Rogelio Bardinas Rodriguez
Family Medicine · Miami, FLNPI 1043458326
Payments from drug & device makers
Across 274 payments — averaging $1096.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- BD$208K
- Boehringer Ingelheim$48K
- Novartis$32K
- Boehringer Ingelheim Pharma GmbH & Co.kg$7K
- Johnson & Johnson$1K
- Boehringer Ingelheim International GmbH$1K
- plus $3K from 16 others
What the payments were for
- Food & beverage$4,87595%
- Education$2355%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| BD | 5 | $207,554 |
| Boehringer Ingelheim | 22 | $48,383 |
| Novartis | 8 | $32,060 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 1 | $6,677 |
| Johnson & Johnson | 67 | $1,457 |
| Boehringer Ingelheim International GmbH | 10 | $1,117 |
| Lilly USA, LLC | 44 | $660 |
| AstraZeneca | 30 | $479 |
| GSK | 12 | $435 |
| Sanofi-aventis U.S. LLC | 22 | $370 |
| Novo Nordisk | 18 | $309 |
| Astellas Pharma US Inc | 5 | $205 |
| Amarin Pharma, Inc. | 3 | $145 |
| Exact Sciences | 2 | $132 |
| Bayer | 5 | $109 |
| E.r. Squibb & Sons, L.L.C. | 5 | $103 |
| Sunovion Pharmaceuticals Inc. | 5 | $83 |
| Kowa Pharmaceuticals America, Inc. | 3 | $48 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $46 |
| Pfizer | 2 | $35 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Amgen | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$355
- TRELEGY ELLIPTA$246
- Vascepa$125
- INVOKANA$121
- The Cologuard Plus Collection Kit$114
How this compares
$300,443 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 169 | $102,286 |
| XareltoRivaroxaban | 109 | $67,034 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 85 | $62,235 |
| JardianceEmpagliflozin | 84 | $56,783 |
| EntrestoSacubitril/Valsartan | 80 | $53,157 |
| FarxigaDapagliflozin Propanediol | 49 | $28,989 |
| SynjardyEmpagliflozin/Metformin Hcl | 40 | $23,226 |
| OzempicSemaglutide | 18 | $16,597 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 174 | $13,967 |
| MyrbetriqMirabegron | 23 | $13,738 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $13,149 |
| Alcohol Prep PadsAlcohol Antiseptic Pads | 737 | $13,104 |
| TrulicityDulaglutide | 12 | $12,438 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $9,658 |
| Spiriva HandihalerTiotropium Bromide | 16 | $7,728 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $35 | $102,286169 claims |
| Boehringer IngelheimJardiance, Synjardy | $48,383 | $80,009124 claims |
| Johnson & JohnsonXarelto | $1,457 | $67,034109 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $370 | $62,23585 claims |
| NovartisEntresto | $32,060 | $53,15780 claims |
| AstraZenecaFarxiga, Symbicort | $479 | $34,05471 claims |
| Novo NordiskOzempic | $309 | $16,59718 claims |
| Astellas Pharma US IncMyrbetriq | $205 | $13,73823 claims |
| Lilly USA, LLCTrulicity | $660 | $12,43812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Miami
- Keila HooverMiami$33.7M
- Jorge CasoMiami$22.6M
- David WyattMiami$13.7M
- Jose CardenasMiami$13.2M
- Lazaro GarciaMiami$10.3M
- Ibrahim Menendez PerezMiami$8.9M
- Aniel Navarro MarinMiami$7.3M
- Gilberto SecoMiami$6.8M
- Ramon LeonMiami$6.3M
- Eddy CapoteMiami$6.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.